Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the …
MA Shah, T Kojima, D Hochhauser, P Enzinger… - JAMA …, 2019 - jamanetwork.com
Importance Effective treatment options are limited for patients with advanced, metastatic
esophageal cancer progressing after 2 or more lines of systemic therapy. Objective To
evaluate the efficacy and safety of pembrolizumab for patients with advanced, metastatic
esophageal squamous cell carcinoma (ESCC) or advanced, metastatic adenocarcinoma of
the esophagus and gastroesophageal junction that progressed after 2 or more lines of
systemic therapy. Design, Setting, and Participants This phase 2, open-label, interventional …
esophageal cancer progressing after 2 or more lines of systemic therapy. Objective To
evaluate the efficacy and safety of pembrolizumab for patients with advanced, metastatic
esophageal squamous cell carcinoma (ESCC) or advanced, metastatic adenocarcinoma of
the esophagus and gastroesophageal junction that progressed after 2 or more lines of
systemic therapy. Design, Setting, and Participants This phase 2, open-label, interventional …